Recurrence of H Pylori : Incidence and Influential Factors.
Not Applicable
Recruiting
- Conditions
- H. Pylori Infection
- Registration Number
- NCT07045857
- Lead Sponsor
- Sohag University
- Brief Summary
This study aims to determine recurrence rates, identify influential factors, investigate key factors that contribute to recurrence, evaluate treatment effectiveness and to assess the efficacy of different eradication regimens and their role in reducing recurrence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Age: 18-75 years old.
- H. pylori infection: Confirmed by endoscopy, biopsy, or non-invasive tests (e.g., urea breath test, stool antigen test).
- Symptoms: Presence of dyspepsia, peptic ulcer disease, or other H. pylori-related symptoms.
- Laboratory tests: Normal liver and kidney function, and no significant abnormalities in blood counts.
Exclusion Criteria
- Patients receiving eradication therapy in the past taking proton pump inhibitors,, H2 blockers ,,bismuth ,, antibiotics or other medications that interfere with the result of the examination in the recent 4 weeks.
- Gastrointestinal disorders: Severe gastrointestinal disorders (e.g., gastric cancer, inflammatory bowel disease ,gastric or duodenal ulcer with current or recent bleeding , or clinical significant gastrointestinal bleeding within 4 weeks of randomization).
- Malignancies: Active or recent malignancies.
- Severe comorbidities: Unstable or severe comorbidities (e.g., heart failure, liver cirrhosis).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method recurrence of H. Pylori infection in patients who recieved medical treatment 4 weeks after successful medical treatment H. Pylori antigen in stool
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms drive H. pylori recurrence post-eradication therapy in Sohag Government?
How do novel eradication regimens compare to standard triple therapy in reducing H. pylori recurrence rates?
Which biomarkers correlate with treatment response and recurrence risk in H. pylori-infected patients?
What are the most common adverse events associated with H. pylori eradication protocols in clinical practice?
Are combination therapies involving proton pump inhibitors more effective than monotherapies for H. pylori recurrence prevention?
Trial Locations
- Locations (1)
Sohag University Hospital
🇪🇬Sohag, Egypt
Sohag University Hospital🇪🇬Sohag, EgyptMagdy M Amin, ProfessorContact01090801900